New treatment options for infections caused by multiresistant strains of pseudomonas aeruginosa and other nonfermenting gram-negative bacilli

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 2, 2011, Pages 151-158

  Sánchez, Anna ^a   Gattarello, Simone ^a   Rello, Jordi ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acinetobacter baumannii; cystic fibrosis; health associated infections; Multiresistant nonfermenting bacilli; pneumonia; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DORIPENEM; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; NETILMICIN; PIPERACILLIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLONE DERIVATIVE; SITAFLOXACIN; TAZOBACTAM; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BURKHOLDERIA CEPACIA INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SKIN INFECTION; STENOTROPHOMONAS MALTOPHILIA; SURGICAL INFECTION; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 79955044483     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1275527     Document Type: Article

References (92)

1. Klevens R M., Edwards J R., Richards C L. Jr et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007 122 2 160-166
2. Chopra I, Schofield C, Everett M et al. Treatment of health-care- associated infections caused by gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008 8 2 133-139
3. Peleg A Y., Hooper D C. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010 362 19 1804-1813
4. Diaz E, Munoz E, Agbaht K, Rello J. Management of ventilator-associated pneumonia caused by multiresistant bacteria. Curr Opin Crit Care 2007 13 1 45-50 (Pubitemid 46052169)
5. Rello J, Sa-Borges M, Correa H, Leal S R., Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999 160 2 608-613 (Pubitemid 29380680)
6. Spellberg B, Guidos R, Gilbert D et al, Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008 46 2 155-164 (Pubitemid 351269151)
7. Boucher H W., Talbot G H., Bradley J S. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009 48 1 1-12
8. Rice L B. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009 12 5 476-481
9. Schulert G S., Feltman H, Rabin S DP et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003 188 11 1695-1706 (Pubitemid 38010681)
10. Talbot G H., Bradley J, Edwards J E. Jr, Gilbert D, Scheld M, Bartlett J G., Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006 42 5 657-668 (Pubitemid 43271379)
11. McGowan J E. Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006 119 6, Suppl 1 S29-S36 discussion S62-S70 (Pubitemid 43776143)
12. Rice L B. Unmet medical needs in antibacterial therapy. Biochem Pharmacol 2006 71 7 991-995
13. Mesaros N, Nordmann P, Plésiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007 13 6 560-578 (Pubitemid 46730662)
14. Hidron A I., Edwards J R., Patel J et al, National Healthcare Safety Network Team Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008 29 11 996-1011
15. Paterson D L., Lipman J. Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit Care Med 2007 35 7 1789-1791 (Pubitemid 46985895)
16. Valencia R, Arroyo L A., Conde M et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009 30 3 257-263
17. Paterson D L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006 43 Suppl 2 S43-S48 (Pubitemid 44267139)
18. Pinheiro M R., Lacerda H R., Melo R G., Maciel M A. Pseudomonas aeruginosa infections: factors relating to mortality with emphasis on resistance pattern and antimicrobial treatment. Braz J Infect Dis 2008 12 6 509-515
19. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006 50 1 43-48 (Pubitemid 43042900)
20. Gaynes R, Edwards J R., National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005 41 6 848-854 (Pubitemid 41266753)
21. Koulenti D, Lisboa T, Brun-Buisson C et al, EU-VAP/CAP Study Group. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009 37 8 2360-2368
22. Gilligan P H. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991 4 1 35-51 (Pubitemid 21920386)
23. Martinez-Solano L, Macia M D., Fajardo A, Oliver A, Martinez J L. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008 47 12 1526-1533
24. Chastre J, Fagon J Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002 165 7 867-903 (Pubitemid 34774654)
25. Marshall J C., Christou N V., Meakins J L. The gastrointestinal tract: the undrained abscess of multiple organ failure. Ann Surg 1993 218 2 111-119 (Pubitemid 23229136)
26. Vincent J L. Nosocomial infections in adult intensive-care units. Lancet 2003 361 9374 2068-2077
27. Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006 36 2 78-91 (Pubitemid 43294628)
28. Woods D E. Comparative genomic analysis of Pseudomonas aeruginosa virulence. Trends Microbiol 2004 12 10 437-439 (Pubitemid 39286119)
29. Lambert P A. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med 2002 95 Suppl 41 22-26 (Pubitemid 34713187)
30. Hauser A R., Cobb E, Bodi M et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002 30 3 521-528 (Pubitemid 34214611)
31. Lisboa T, Rello J. Finding the hidden target in Pseudomonas aeruginosa management. Crit Care Med 2008 36 9 2675-2676
32. Queenan A M., Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007 20 3 440-458
33. Juan Nicolau C, Oliver A. Carbapenemases in Pseudomonas spp. Enferm Infecc Microbiol Clin 2010 28 Suppl 1 19-28
34. Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 2009 69 14 1879-1901
35. Kallen A J., Hidron A I., Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010 31 5 528-531
36. Veesenmeyer J L., Hauser A R., Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 2009 37 5 1777-1786
37. Eggimann P, Revelly J P. Should antibiotic combinations be used to treat ventilator-associated pneumonia? Semin Respir Crit Care Med 2006 27 1 68-81 (Pubitemid 43336536)
38. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007 35 8 1888-1895 (Pubitemid 47220363)
39. Sandiumenge A, Diaz E, Bodi M, Rello J. Therapy of ventilator-associated pneumonia: a patient-based approach based on the ten rules of The Tarragona Strategy Intensive Care Med 2003 29 6 876-883 (Pubitemid 36789779)
40. Adeboyeku D, Scott S, Hodson M E. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006 5 4 261-263 (Pubitemid 44824863)
41. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003 3 CD001021
42. Rappaz I, Decosterd L A., Bille J, Pilet M, Bélaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000 159 12 919-925
43. Falagas M E., Kasiakou S K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005 40 9 1333-1341 (Pubitemid 40570245)
44. Li J, Nation R L. Old polymyxins are back: is resistance close? Clin Infect Dis 2006 43 5 663-664 (Pubitemid 44267132)
45. Fekety F R. Jr, Norman P S., Cluff L E. The treatment of gram-negative bacillary infections with colistin: the toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962 57 214-229
46. Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K. A new antibiotic colistin produced by spore forming soil bacteria. J Antibiot 1950 3 457-458
47. Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 2009 69 14 1879-1901
48. Gales A C., Reis A O., Jones R N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001 39 1 183-190 (Pubitemid 32059588)
49. Hogardt M, Schmoldt S, Götzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004 54 6 1057-1061 (Pubitemid 40136741)
50. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003 7 5 R78-R83
51. Linden P K., Paterson D L. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006 43 Suppl 2 S89-S94 (Pubitemid 44267146)
52. Plachouras D, Karvanen M, Friberg L E. et al. Population pharmacokinetic analysis of colistin methanelsulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob Agents Chemother 2009 53 6 3430-3436
53. Kumar A, Roberts D, Wood K E. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006 34 6 1589-1596 (Pubitemid 43810035)
54. Koch-Weser J, Sidel V W., Federman E B., Kanarek P, Finer D C., Eaton A E. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970 72 6 857-868
55. Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther 2006 4 4 601-618 (Pubitemid 44523939)
56. Michalopoulos A, Kasiakou S K., Mastora Z, Rellos K, Kapaskelis A M., Falagas M E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005 9 1 R53-R59
57. Hamer D H. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000 162 1 328-330 (Pubitemid 30469842)
58. Cunningham S, Prasad A, Collyer L, Carr S, Lynn I B., Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001 84 5 432-433 (Pubitemid 32411237)
59. Bhavnani S M., Hammel J P., Cirincione B B., Wikler M A., Ambrose P G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005 49 9 3944-3947 (Pubitemid 41233056)
60. Psathas P A., Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin Ther 2008 30 11 2075-2087
61. Ikawa K, Morikawa N, Uehara S et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009 33 3 276-279
62. Poulakou G, Giamarellou H. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opin Investig Drugs 2008 17 5 749-771 (Pubitemid 351843618)
63. Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Int J Antimicrob Agents 2001 17 3 177-188 (Pubitemid 32229895)
64. Lynch A S. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Biochem Pharmacol 2006 71 7 949-956
65. Nakayama K, Ishida Y, Ohtsuka M et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa, II: Achieving activity in vivo through the use of alternative scaffolds. Bioorg Med Chem Lett 2003 13 23 4205-4208 (Pubitemid 37410313)
66. Lomovskaya O, Warren M S., Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001 45 1 105-116 (Pubitemid 32039101)
67. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003 31 10 2478-2482 (Pubitemid 37281732)
68. Baraibar J, Correa H, Mariscal D, Gallego M, Vallés J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest 1997 112 4 1050-1054 (Pubitemid 27446328)
69. Munoz-Price L S., Weinstein R A. Acinetobacter infection. N Engl J Med 2008 358 12 1271-1281
70. Peleg A Y., Seifert H, Paterson D L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008 21 3 538-582
71. Cisneros-Herreros J M., Garnacho-Montero J, Pachon-Ibánez M E. Nosocomial pneumonia due to Acinetobacter baumannii. Enferm Infecc Microbiol Clin 2005 23 Suppl 3 46-51 (Pubitemid 47394842)
72. Alvarez-Lerma F, Palomar M, Insausti J et al, Grupo de Estudio Nacional de Vigilancia de Infeccion Nosocomial en UCI. Infections caused by Acinetobacter spp. in critically ill UCI patients [in Spanish]. Enferm Infecc Microbiol Clin 2005 23 9 533-539 (Pubitemid 41695911)
73. Falagas M E., Bliziotis I A., Siempos I I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006 10 2 R48
74. Falagas M E., Kasiakou S K., Rafailidis P I., Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006 57 6 1251-1254 (Pubitemid 44644437)
75. Wisplinghoff H, Bischoff T, Tallent S M., Seifert H, Wenzel R P., Edmond M B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 39 3 309-317 (Pubitemid 39050477)
76. Fournier P E., Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006 42 5 692-699 (Pubitemid 43271386)
77. Jawad A, Heritage J, Snelling A M., Gascoyne-Binzi D M., Hawkey P M. Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol 1996 34 12 2881-2887 (Pubitemid 26389327)
78. Corbella X, Montero A, Pujol M et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000 38 11 4086-4095 (Pubitemid 32233209)
79. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006 58 5 1099-1100
80. Pachon-Ibánez M E., Jiménez-Mejias M E., Pichardo C, Llanos A C., Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004 48 11 4479-4481 (Pubitemid 39434923)
81. Karageorgopoulos D E., Kelesidis T, Kelesidis I, Falagas M E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008 62 1 45-55 (Pubitemid 351865873)
82. Rice L B. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006 43 Suppl 2 S100-S105 (Pubitemid 44267148)
83. Levin A S., Levy C E., Manrique A E., Medeiros E A., Costa S F. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003 21 1 58-62 (Pubitemid 36043975)
84. Levin A S., Barone A A., Penço J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999 28 5 1008-1011 (Pubitemid 29203530)
85. Bottone E J., Reitano M, Janda J M., Troy K, Cuttner J. Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum. J Clin Microbiol 1986 24 6 995-997 (Pubitemid 17193356)
86. Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 2004 48 1 151-160 (Pubitemid 38040191)
87. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004 17 1 57-71 (Pubitemid 38120929)
88. Avgeri S G., Matthaiou D K., Dimopoulos G, Grammatikos A P., Falagas M E. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 2009 33 5 394-404
89. Sedlak-Weinstein E, Cripps A W., Kyd J M., Foxwell A R. Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opin Biol Ther 2005 5 7 967-982 (Pubitemid 41032852)
90. Ambrose P G., Bhavnani S M., Ellis-Grosse E J., Drusano G L. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 2010 51 Suppl 1 S103-S110
91. Moriyama B, Henning S A., Childs R et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010 44 5 929-935
92. Lu Q, Rouby J J., Laterre P F. et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosomial Pseudomonal aeruginosa 011 pneumonia. J Antimicrob Chemother [E-pub ahead of print March 10, 2011]